Minimal residual disease in chronic myeloid leukemiaLOWENBERG, Bob.The New England journal of medicine. 2003, Vol 349, Num 15, pp 1399-1401, issn 0028-4793, 3 p.Article

Sense and nonsense of high-dose cytarabine for acute myeloid leukemiaLÖWENBERG, Bob.Blood. 2013, Vol 121, Num 1, pp 26-28, issn 0006-4971, 3 p.Article

Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemiaBREEMS, Dimitri A; LÖWENBERG, Bob.British journal of haematology. 2005, Vol 130, Num 6, pp 825-833, issn 0007-1048, 9 p.Article

Prognostic factors in acute myeloid leukaemiaLÖWENBERG, Bob.Baillière's best practice & research. Clinical haematology. 2001, Vol 14, Num 1, pp 65-75, issn 1521-6926Article

Managing therapy in older adult patients with acute myeloid leukemiaLÖWENBERG, Bob.Seminars in hematology. 2001, Vol 38, Num 3, pp 10-16, issn 0037-1963, SUP6Article

Acute promyelocytic leukemia with a PLZF-RARα fusion proteinJANSEN, Joop H; LÖWENBERG, Bob.Seminars in hematology. 2001, Vol 38, Num 1, pp 37-41, issn 0037-1963Article

A decade of genorne-wide gene expression profiling in acute myeloid leukemia : flashback and prospectsWOUTERS, Bas J; LÖWENBERG, Bob; DELWEL, Ruud et al.Blood. 2009, Vol 113, Num 2, pp 291-298, issn 0006-4971, 8 p.Article

Acute myeloid leukemia and the position of autologous stem cell transplantationBREAMS, Dimitri A; LÖWENBERG, Bob.Seminars in hematology. 2007, Vol 44, Num 4, pp 259-266, issn 0037-1963, 8 p.Article

The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiationJORDA, Meritxell Alberich; LÖWENBERG, Bob; DELWEL, Ruud et al.Blood. 2003, Vol 101, Num 4, pp 1336-1343, issn 0006-4971, 8 p.Article

Gene expression profiling in acute myeloid leukemia : Myeloid diseaseVALK, Peter J. M; DELWEL, Ruud; LÖWENBERG, Bob et al.Current opinion in hematology. 2005, Vol 12, Num 1, pp 76-81, issn 1065-6251, 6 p.Article

Therapeutic Advances in Acute Myeloid LeukemiaBURNETT, Alan; WETZLER, Meir; LÖWENBERG, Bob et al.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 487-494, issn 0732-183X, 8 p.Article

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemiaROMBOUTS, Elwin J. C; PAVIC, Biljana; LÖWENBERG, Bob et al.Blood. 2004, Vol 104, Num 2, pp 550-557, issn 0006-4971, 8 p.Article

Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNetSANZ, Miguel A; GRIMWADE, David; BURNETT, Alan K et al.Blood. 2009, Vol 113, Num 9, pp 1875-1891, issn 0006-4971, 17 p.Article

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaCHESON, Bruce D; GREENBERG, Peter L; MITTELMAN, Moshe et al.Blood. 2006, Vol 108, Num 2, pp 419-425, issn 0006-4971, 7 p.Article

Monosomal Karyotype in Acute Myeloid Leukemia : A Better Indicator of Poor Prognosis Than a Complex KaryotypeBREEMS, Dimitri A; VAN PUTTEN, Wim L. J; LOWENBERG, Bob et al.Journal of clinical oncology. 2008, Vol 26, Num 29, pp 4791-4797, issn 0732-183X, 7 p.Article

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1WOUTERS, Bas J; ALBERICH JORDA, Meritxell; HETHERINGTON, Christopher J et al.Blood. 2007, Vol 110, Num 10, pp 3706-3714, issn 0006-4971, 9 p.Article

A phase I first-in-human study with tefinostat ― a monocyte/ macrophage targeted histone deacetylase inhibitor ― in patients with advanced haematological malignanciesOSSENKOPPELE, Gert J; LOWENBERG, Bob; TOAL, Martin et al.British journal of haematology. 2013, Vol 162, Num 2, pp 191-201, issn 0007-1048, 11 p.Article

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimensMONTESINOS, Pau; RAYON, Chelo; RIVAS, Concha et al.Blood. 2011, Vol 117, Num 6, pp 1799-1805, issn 0006-4971, 7 p.Article

Evidence for Acute Neurotoxicity after ChemotherapyPETZOLD, Axel; MONDRIA, Tjeerd; HINTZEN, Rogier et al.Annals of neurology. 2010, Vol 68, Num 6, pp 806-815, issn 0364-5134, 10 p.Article

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxisMONTESINOS, Pau; DIAZ-MEDIAVILLA, Joaquin; GONZALEZ, José et al.Haematologica (Roma). 2009, Vol 94, Num 9, pp 1242-1249, issn 0390-6078, 8 p.Article

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy : characteristics, outcome, and prognostic factorsMONTESINOS, Pau; BERGUA, Juan M; RIVAS, Concha et al.Blood. 2009, Vol 113, Num 4, pp 775-783, issn 0006-4971, 9 p.Article

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative StudyZEJUAN LI; HEROLD, Tobias; XINAN YANG et al.Journal of clinical oncology. 2013, Vol 31, Num 9, pp 1172-1181, issn 0732-183X, 10 p.Article

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapyCERVERA, José; MONTESINOS, Pau; MILONE, Gustavo et al.Haematologica (Roma). 2010, Vol 95, Num 3, pp 424-431, issn 0390-6078, 8 p.Article

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeSANZ, Miguel A; MONTESINOS, Pau; RIVAS, Concha et al.Blood. 2010, Vol 115, Num 25, pp 5137-5146, issn 0006-4971, 10 p.Article

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy : long-term outcome of the LPA 99 multicenter study by the PETHEMA GroupSANZ, Miguel A; MONTESINOS, Pau; RIVAS, Concha et al.Blood. 2008, Vol 112, Num 8, pp 3130-3134, issn 0006-4971, 5 p.Article